Dimensional Fund Advisors LP Raises Stock Holdings in Amneal Pharmaceuticals, Inc. $AMRX

Dimensional Fund Advisors LP increased its stake in Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) by 1.5% during the 1st quarter, Holdings Channel reports. The firm owned 5,690,586 shares of the company’s stock after purchasing an additional 81,546 shares during the quarter. Dimensional Fund Advisors LP’s holdings in Amneal Pharmaceuticals were worth $70,723,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also bought and sold shares of AMRX. Westshore Wealth LLC bought a new stake in Amneal Pharmaceuticals during the third quarter valued at approximately $13,833,000. Morgan Stanley increased its holdings in shares of Amneal Pharmaceuticals by 37.5% in the 4th quarter. Morgan Stanley now owns 4,818,099 shares of the company’s stock worth $60,708,000 after buying an additional 1,315,018 shares during the last quarter. Allspring Global Investments Holdings LLC raised its position in shares of Amneal Pharmaceuticals by 72.2% during the 1st quarter. Allspring Global Investments Holdings LLC now owns 2,549,572 shares of the company’s stock valued at $32,405,000 after buying an additional 1,069,400 shares in the last quarter. Penn Capital Management Company LLC bought a new stake in shares of Amneal Pharmaceuticals during the 4th quarter worth $12,655,000. Finally, Rubric Capital Management LP lifted its holdings in shares of Amneal Pharmaceuticals by 9.1% during the 2nd quarter. Rubric Capital Management LP now owns 11,710,332 shares of the company’s stock worth $94,737,000 after acquiring an additional 974,355 shares during the last quarter. 31.82% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of research analysts recently commented on AMRX shares. Weiss Ratings raised Amneal Pharmaceuticals from a “hold (c+)” rating to a “buy (b-)” rating in a research note on Wednesday. UBS Group upped their price objective on Amneal Pharmaceuticals from $19.00 to $23.00 and gave the stock a “buy” rating in a report on Wednesday, July 15th. Zacks Research lowered Amneal Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Monday, April 6th. The Goldman Sachs Group reissued a “buy” rating and set a $21.00 price objective on shares of Amneal Pharmaceuticals in a report on Friday. Finally, Wall Street Zen upgraded Amneal Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research report on Sunday, July 12th. Seven analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $17.33.

Insider Buying and Selling at Amneal Pharmaceuticals

In related news, Director Deborah M. Autor sold 34,819 shares of the stock in a transaction dated Monday, May 11th. The stock was sold at an average price of $12.94, for a total transaction of $450,557.86. Following the completion of the sale, the director directly owned 93,660 shares in the company, valued at $1,211,960.40. This represents a 27.10% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. Company insiders own 17.30% of the company’s stock.

Amneal Pharmaceuticals Price Performance

AMRX stock opened at $18.32 on Friday. The firm has a market cap of $5.84 billion, a P/E ratio of 37.39 and a beta of 1.26. The firm’s fifty day moving average is $16.23 and its 200 day moving average is $14.26. Amneal Pharmaceuticals, Inc. has a 52 week low of $7.66 and a 52 week high of $19.26. The company has a debt-to-equity ratio of 77.65, a quick ratio of 1.59 and a current ratio of 2.20.

Amneal Pharmaceuticals (NASDAQ:AMRX) last posted its quarterly earnings results on Thursday, May 7th. The company reported $0.27 earnings per share for the quarter. Amneal Pharmaceuticals had a net margin of 5.05% and a negative return on equity of 584.46%. The business had revenue of $722.52 million during the quarter. Research analysts predict that Amneal Pharmaceuticals, Inc. will post 0.92 earnings per share for the current year.

Amneal Pharmaceuticals News Roundup

Here are the key news stories impacting Amneal Pharmaceuticals this week:

• Positive Sentiment: Q2 results exceeded expectations. Amneal reported revenue of approximately $796 million, GAAP net income of $58 million, adjusted EBITDA of $206 million and adjusted diluted EPS of $0.30, above the $0.24 analyst consensus and up from $0.25 a year earlier. Amneal Reports Second Quarter 2026 Financial Results
• Positive Sentiment: Full-year revenue guidance was raised. Management now expects 2026 revenue of $3.1 billion to $3.2 billion, compared with a prior outlook near $3.1 billion, suggesting continued confidence in demand and operating performance. AMRX Down Despite Q2 Earnings Beat, 2026 Revenue Outlook Raised
• Positive Sentiment: Debt repricing should reduce interest expense. The company completed a July debt repricing, which is expected to lower borrowing costs and support future earnings and cash flow. Amneal Reports Second Quarter 2026 Financial Results
• Neutral Sentiment: EPS guidance was broadly in line with consensus. Amneal forecast 2026 EPS of $0.96 to $1.06 versus the $0.97 consensus estimate. While the midpoint is slightly above expectations, the range does not represent a major upward revision.
• Negative Sentiment: Investors may be taking profits after the earnings-driven rally. The strong quarterly beat and revenue outlook improvement were likely already reflected in the stock after its recent advance, leaving limited upside when full-year earnings guidance was only modestly better than expectations. Amneal beats expectations in strong Q2 2026

Amneal Pharmaceuticals Company Profile

Amneal Pharmaceuticals, Inc is a publicly traded integrated healthcare company specializing in the development, manufacturing and distribution of generic and specialty pharmaceutical products. The company’s portfolio includes oral solids, injectables, transdermals and biosimilars, serving a broad range of therapeutic areas such as cardiovascular, neuroscience, oncology and women’s health. Alongside its generic offerings, Amneal has built a branded portfolio through strategic acquisitions and internal development, positioning itself across both high-volume generics and higher-value specialty treatments.

Since its founding in 2002 by brothers Chirag and Chintu Modgil, Amneal has pursued growth through organic investment in research and development as well as targeted M&A.